医師調剤コスメシューティカルの世界市場：2025年～2033年

医師調剤コスメシューティカルの世界市場は、2024年に365億5,000万米ドルに達し、2033年までには698億4,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは7.8%で成長する見込みです。

医師調剤コスメシューティカルは、化粧品と医薬品の交差点に存在する製品です。市販の化粧品とは異なり、これらの製品は医学的に管理された環境で調剤され、角質層の下にある皮膚に実際の生物学的効果をもたらすことを目的としています。このカテゴリーには、アンチエイジング、にきび治療、肌の若返りといった問題をターゲットとしたスキンケア製品、頭皮の健康や抜け毛に対処するヘアケア製品、ドライアイ症候群のような症状の治療や化粧品としての機能強化を含むアイケア製品など、様々な処方が含まれます。

医師調剤コスメシューティカルの世界市場とは、皮膚科医や形成外科医などの医療専門家を通じてのみ入手可能な化粧品を含む、スキンケア産業の一分野を指します。これらの製品は、医薬品グレードの成分を化粧品製剤に配合することで臨床的効果を発揮するよう処方されており、加齢、にきび、色素沈着、肌の健康全般など、特定の肌悩みに効果的に対応します。

効果的なスキンケアソリューションに対する消費者の需要が高まり続ける中、皮膚科学分野の進歩やプロフェッショナルグレードの製品の利点に対する意識の高まりにより、医師調剤コスメシューティカルズ市場は大きく成長すると予想されます。このような要因が、世界の医師調剤コスメシューティカル市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

美容意識の高まり

美容意識の高まりは、消費者の外見や肌の健康に対する意識が高まっている広範な動向を反映したもので、世界の医師主導型コスメシューティカルズ市場成長の重要な要因となっています。この意識の高まりは購買行動に影響を与え、いくつかの重要な方法で市場力学を形成しています。

肌の健康に対する意識が高まるにつれ、消費者は見た目を美しくするだけでなく、根本的な肌の問題に対処する製品を求めるようになります。このため、医師調剤コスメシューティカルへの関心が高まっています。コスメシューティカルは、医薬品グレードの成分を化粧品に配合し、老化、にきび、色素沈着などの症状に対して臨床的な効果をもたらします。消費者はスキンケア製品の成分についてますます知識を深めています。合成化学物質の潜在的な有害性への懸念から、天然成分やオーガニック成分を求める方向にシフトしています。多くの消費者は現在、クリーンビューティー運動に合わせて、クリーンまたは有害な添加物不使用と表示された製品を好んでいます。

ソーシャルメディア・プラットフォームは、美容意識の増幅に重要な役割を果たしています。インフルエンサーや美容専門家は、しばしばスキンケア方法やお勧めの製品を紹介し、消費者は市場で入手可能な効果的な解決策をより意識するようになります。この動向は、より良い結果を約束する医師が処方する製品の探求を個人に促しています。美容意識が高まるにつれて、消費者は自分のニーズに合わせてカスタマイズされたスキンケア・ソリューションをますます期待するようになっています。このようなカスタマイズの需要は、ブランド各社を革新に駆り立て、個々の肌タイプや悩みに対応した製品を提供するようになります。

さらに、業界の主要企業は、革新的なプラットフォームを導入し、この世界の医師調剤コスメシューティカルズ市場の成長を促進する主要な拡張を行っています。例えば、2024年3月、Elevai Labsは、197億米ドルの世界の医師調剤コスメシューティカル市場におけるディスラプターとしての急成長を促進するため、eコマースポータルを立ち上げました。この新しいオンライン・プラットフォームにより、消費者はElevaiのスキンケア製品を直接購入できるようになり、主にヘルスケア専門家を通じて販売していた従来の企業間取引（B2B）モデルから大きく転換しました。これらすべての要因が、世界の医師調剤コスメシューティカル市場に需要をもたらしています。

また、2024年12月にはエレバイ・ラボ社がSシリーズ・ルート・リニューアル・システムを発表し、完全子会社であるエレバイ・スキンケア社を通じてヘアケア市場に大きく参入しました。この革新的なシステムは、シャンプー、コンディショナー、美容液の3つの主要コンポーネントで構成され、最先端技術を駆使して細胞レベルで髪と頭皮の健康を促進するよう設計されています。さらに、スキンケア技術の進歩に対する需要の高まりが、世界の医師調剤コスメシューティカルズ市場の拡大に寄与しています。

製品コストの高騰 / 熟練専門家の不足

熟練した専門家の不足は、世界の医師調剤コスメシューティカルズ市場における大きな抑制要因であり、消費者の需要増に効果的に対応する業界の能力に影響を与えています。医師調剤コスメシューティカル部門は現在、深刻な採用難に直面しています。多くの企業が、皮膚科医、美容施術師、訓練を受けたスキンケアの専門家など、必要不可欠な役割を満たすのに苦労しています。この不足は、効果的なコスメシューティカル製品を調剤し、推奨できる有資格の専門家の利用を制限し、最終的にサービスの提供と消費者の信頼に影響を与えます。

美容とスキンケアの分野では、トレーニングや資格の格差が目立っています。見習い制度や職業訓練プログラムなど、この業界に入るための伝統的な道筋は、新しい才能を惹きつけることに失敗しています。消費者がそれぞれのニーズに合わせたスキンケアを求めるようになるにつれ、個々の肌タイプを見極め、医師が処方する適切な製品を推奨できる熟練した専門家への需要が高まっています。しかし、有能な人材が不足しているため、この需要に応えることはますます課題となっています。したがって、上記の要因は、世界の医師調剤コスメシューティカルズ市場の潜在的な成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 美意識の高まり
  • 抑制要因
    • 製品コストの高騰/熟練した専門家の不足
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• スキンケア製品
  • アンチエイジング
  • 日焼け止め
  • ニキビ
  • 保湿クリーム・美容液
  • 皮膚充填剤
  • その他
• ヘアケア製品
  • 育毛促進剤
  • フケ防止
  • 頭皮修復ソリューション
  • その他
• アイケア製品
  • 目薬
  • アイクリーム・ジェル
  • その他
• その他

第7章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Allergan（AbbVie Inc.）
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Merz Pharma
• Obagi Cosmeceuticals LLC.
• L'Oreal Groupe
• SkinCeuticals.
• ZO Skin Health, Inc.
• JMSR, Inc.
• La Roche-Posay
• Galderma
• ELEVAI Labs, Inc.
• Sebapharma
• Cosmetic Skin Solutions.
• AestheticsRX
• RATIONALE.

第11章 付録

The global physician-dispensed cosmeceuticals market reached US$ 36.55 billion in 2024 and is expected to reach US$ 69.84 billion by 2033, growing at a CAGR of 7.8 % during the forecast period 2025-2033.

Physician-dispensed cosmeceuticals are products that exist at the intersection of cosmetics and pharmaceuticals. Unlike over-the-counter cosmetics, these products are dispensed in a medically supervised environment and are intended to produce actual biological effects on the skin beneath the stratum corneum. This category encompasses a variety of formulations, including skincare products targeting issues such as anti-aging, acne treatment, and skin rejuvenation, hair care products addressing scalp health and hair loss, and eye care products including treatments for conditions like dry eye syndrome or cosmetic enhancements.

The global physician-dispensed cosmeceuticals market refers to a segment of the skincare industry that includes cosmetic products available exclusively through healthcare professionals, such as dermatologists and plastic surgeons. These products are formulated to provide clinical benefits by combining pharmaceutical-grade ingredients with cosmetic formulations, effectively addressing specific skin concerns, including aging, acne, hyperpigmentation, and overall skin health.

As consumer demand for effective skincare solutions continues to rise, the market for physician-dispensed cosmeceuticals is expected to grow significantly, driven by advancements in dermatological science and increasing awareness of the benefits of professional-grade products. These factors have driven the global physician-dispensed cosmeceuticals market expansion.

Market Dynamics: Drivers & Restraints

Increasing Beauty Consciousness

Increasing beauty consciousness is a significant driver of growth in the global physician-dispensed cosmeceuticals market, reflecting a broader trend where consumers are becoming more aware of their appearance and skin health. This heightened awareness influences purchasing behaviors and shapes market dynamics in several key ways.

As consumers become more conscious of their skin health, they seek products that not only enhance their appearance but also address underlying skin issues. This has led to a growing interest in physician-dispensed cosmeceuticals, which combine pharmaceutical-grade ingredients with cosmetic formulations to deliver clinical results for conditions like aging, acne, and hyperpigmentation. Consumers are increasingly knowledgeable about the ingredients in their skincare products. There is a shift towards seeking natural and organic ingredients, driven by concerns over the potential harmful effects of synthetic chemicals. Many consumers now prefer products that are labeled as clean or free from harmful additives, aligning with the clean beauty movement.

Social media platforms have played a crucial role in amplifying beauty consciousness. Influencers and beauty experts often share their skincare routines and product recommendations, making consumers more aware of effective solutions available in the market. This trend encourages individuals to explore physician-dispensed products that promise better results. As beauty consciousness rises, consumers increasingly expect personalized skincare solutions tailored to their specific needs. This demand for customization drives brands to innovate and offer products that cater to individual skin types and concerns.

Furthermore, major players in the industry introducing innovative platforms and key expansion that would drive this global physician-dispensed cosmeceuticals market growth. For instance, in March 2024, Elevai Labs launched an e-commerce portal to facilitate its rapid growth as a disruptor in the $19.7 billion global physician-dispensed cosmeceutical market. This new online platform allows consumers to directly purchase Elevai's skincare products, marking a significant shift from its previous business-to-business (B2B) model that primarily involved sales through healthcare professionals. All these factors demand the global physician-dispensed cosmeceuticals market.

Also, in December 2024, Elevai Labs Inc. the S-Series Root Renewal System, marking a significant entry into the hair care market through its wholly owned subsidiary, Elevai Skincare Inc. This innovative system comprises three key components: a shampoo, conditioner, and serum, all designed to promote hair and scalp health at the cellular level using cutting-edge technologies. Moreover, the rising demand for advancements in skincare technology contributes to the global physician-dispensed cosmeceuticals market expansion.

High Costs of Products/Shortage of Skilled Professionals

The shortage of skilled professionals is a significant restraint in the global physician-dispensed cosmeceuticals market, impacting the industry's capacity to effectively meet rising consumer demand. The physician-dispensed cosmeceuticals sector is currently facing a serious recruitment crisis. Many businesses struggle to fill essential roles, such as dermatologists, aesthetic practitioners, and trained skincare specialists. This shortage limits the availability of qualified professionals who can dispense and recommend effective cosmeceutical products, ultimately affecting service delivery and consumer trust.

There are notable gaps in training and qualifications within the beauty and skincare sectors. Traditional pathways into the industry, such as apprenticeships and vocational training programs, are failing to attract new talent. As consumers increasingly seek personalized skincare solutions tailored to their specific needs, there is a growing demand for skilled professionals who can assess individual skin types and recommend appropriate physician-dispensed products. However, with a shortage of qualified personnel, meeting this demand becomes increasingly challenging. Thus, the above factors could be limiting the global physician-dispensed cosmeceuticals market's potential growth.

Segment Analysis

The global physician-dispensed cosmeceuticals market is segmented based on product type, distribution channel, and region.

Product Type:

The skin care products segment is expected to dominate the global physician-dispensed cosmeceuticals market share

The skin care products segment holds a major portion of the global physician-dispensed cosmeceuticals market share and is expected to continue to hold a significant portion of the global physician-dispensed cosmeceuticals market share during the forecast period.

This segment encompasses a variety of formulations designed to address specific skin concerns, leveraging pharmaceutical-grade ingredients that provide clinical benefits. The skin care products segment includes various categories, such as anti-aging products, acne treatment solutions, skin whitening and hyperpigmentation treatments, and dermal fillers. The increasing awareness of skin health and beauty consciousness among consumers drives demand for effective skincare solutions. As individuals become more discerning about their skincare choices, they seek products that not only enhance appearance but also address underlying skin issues.

Furthermore, key players in the industry introducing new products in the market that would drive this segment growth in the global physician-dispensed cosmeceuticals market. For instance, in April 2024, Allergan Aesthetics unveiled two new products under its SkinMedica brand the SkinMedica Acne Clarifying Treatment and the SkinMedica Pore Purifying Gel Cleanser. These innovative products are specifically formulated for individuals with acne-prone skin, providing effective and balanced skincare solutions.

Also, in February 2023, Galderma introduced Alastin Skincare ReSURFACE Skin Polish, a new addition to its scientifically formulated skincare line. This innovative product is designed to improve skin texture by effectively removing dead skin cells and impurities, resulting in smoother and visibly brighter skin.

These factors have solidified the segment's position in the global physician-dispensed cosmeceuticals market.

Geographical Analysis

North America is expected to hold a significant position in the global physician-dispensed cosmeceuticals market share

North America holds a substantial position in the global physician-dispensed cosmeceuticals market and is expected to hold most of the market share.

Consumers are becoming more aware of their appearance and skin health, leading to a heightened demand for effective skincare solutions. This awareness encourages individuals to seek products that not only enhance aesthetics but also address underlying skin issues, driving interest in physician-dispensed cosmeceuticals. Skin diseases, such as acne, affect approximately 50 million people annually in the U.S. The increasing prevalence of various skin conditions creates a demand for specialized products that provide clinical benefits, further propelling market growth.

The aging demographic in North America is contributing to a greater focus on anti-aging treatments. As consumers strive to maintain a youthful appearance, there is a growing demand for products that target signs of aging, such as wrinkles and fine lines. Physician-dispensed cosmeceuticals are recognized for their ability to deliver tangible results due to their pharmaceutical-grade ingredients. Consumers increasingly seek products that provide proven efficacy in treating various skin concerns, which drives them toward these specialized options.

Social media platforms significantly shape consumer perceptions about beauty and skincare products. Influencers and beauty experts often promote physician-dispensed cosmeceuticals, increasing awareness and interest among consumers looking for effective solutions. As beauty consciousness rises, there is an expectation for personalized skincare solutions tailored to individual needs. This trend encourages brands to innovate and offer customized products that cater to specific skin types and concerns.

Furthermore, key player's strategies such as partnerships & collaborations, and launches would drive this global physician-dispensed cosmeceuticals market growth. For instance, in January 2025, Young Pharmaceuticals Inc. announced an exclusive distribution partnership with LAC2Biome, a company specializing in microbial-based product solutions. This collaboration will introduce the BiomeAge product line to the U.S. market, which focuses on a science-driven approach to enhancing skin health.

Also, in October 2023, in California, NovaBay Pharmaceuticals, Inc. launched two new promotional programs aimed at ophthalmologists and optometrists to support their patients in managing chronic dry eye symptoms with Avenova-branded products. The introduction of the Avenova Loyalty Program and the Avenova Affiliate Program provides eyecare professionals with exclusive promotions designed to increase awareness of the complete range of Avenova products. Thus, the above factors are consolidating the region's position as a dominant force in the global physician-dispensed cosmeceuticals market.

Asia Pacific is growing at the fastest pace in the global physician-dispensed cosmeceuticals market share

Asia Pacific holds the fastest pace in the global physician-dispensed cosmeceuticals market and is expected to hold most of the market share.

The prevalence of skin diseases such as acne and hyperpigmentation is on the rise in the Asia-Pacific region. For example, acne affects millions in countries like India and China, creating a demand for specialized products that provide clinical benefits and further propelling market growth. There is a growing awareness among consumers regarding their appearance and skin health. This heightened beauty consciousness drives demand for effective skincare solutions that not only enhance aesthetics but also address underlying skin issues, leading to increased interest in physician-dispensed cosmeceuticals.

Physician-dispensed cosmeceuticals are recognized for their ability to deliver tangible results due to their pharmaceutical-grade ingredients. Consumers are increasingly seeking products that provide proven efficacy in treating various skin concerns, driving them toward these specialized options. Social media platforms play a crucial role in shaping consumer perceptions about beauty and skincare products in the Asia-Pacific region. Influencers and beauty experts often promote physician-dispensed cosmeceuticals, increasing awareness and interest among consumers looking for effective solutions.

Furthermore, key players in the industry introducing new products in the market drive this global physician-dispensed cosmeceuticals market growth. For instance, in January 2025, Obagi Medical launched its products in India through a partnership with Nykaa, the country's premier beauty and lifestyle platform. This collaboration marks a significant milestone in providing high-quality skincare solutions to Indian consumers. With over 30 years of expertise, Obagi Medical is known for its clinically proven products that effectively address various skin concerns, including aging, hyperpigmentation, and uneven skin tone.

Also, in December 2024, Hydrinity Accelerated Skin Science launched its products in India through a partnership with Photonence, a company recognized for its innovative healthcare distribution solutions. This collaboration aims to introduce Hydrinity's range of hyaluronic acid skincare products to the Indian market, leveraging Photonence's expertise and established presence in the medical aesthetics sector. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global physician-dispensed cosmeceuticals market.

Competitive Landscape

The major global players in the physician-dispensed cosmeceuticals market include Allergan (AbbVie Inc.), Merz Pharma, Obagi Cosmeceuticals LLC., L'Oreal Groupe, SkinCeuticals., ZO Skin Health, Inc., JMSR, Inc., La Roche-Posay, Galderma, ELEVAI Labs, Inc., Sebapharma, Cosmetic Skin Solutions., AestheticsRX, and RATIONALE. among others.

Key Developments

• In January 2025, Carmell Corporation announced its entry into a definitive purchase agreement to acquire the assets of Elevai Skincare Inc., a subsidiary of PMGC Holdings Inc. This acquisition is aimed at enhancing Carmell's portfolio in the skincare and haircare sectors.
• In December 2024, CALECIM, officially entered the Indian market, marking a significant milestone in the country's hair restoration industry. This launch is supported by CellResearch Corporation, a pioneering biotechnology firm known for its groundbreaking work in stem cell research over the past two decades.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global physician-dispensed cosmeceuticals market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Distribution channel
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Beauty Consciousness
  • 4.1.2. Restraints
    • 4.1.2.1. High Costs of Products/Shortage of Skilled Professionals
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Skin Care Products*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Anti-Aging
  • 6.2.4. Sunscreens
  • 6.2.5. Acne
  • 6.2.6. Hydrating Creams & Serums
  • 6.2.7. Dermal Fillers
  • 6.2.8. Others
• 6.3. Hair Care Products
  • 6.3.1. Hair Growth Stimulants
  • 6.3.2. Anti-Dandruff
  • 6.3.3. Scalp Repair Solutions
  • 6.3.4. Others
• 6.4. Eye Care Products
  • 6.4.1. Eye Drops
  • 6.4.2. Eye Creams & Gels
  • 6.4.3. Others
• 6.5. Others

7. By Distribution channel

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
  • 7.1.2. Market Attractiveness Index, By Distribution channel
• 7.2. Hospital Pharmacies*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Retail Pharmacies
• 7.4. Online Pharmacies

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution channel

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Allergan (AbbVie Inc.) *
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue's
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals etc.
  • 10.1.5. SWOT Analysis
• 10.2. Merz Pharma
• 10.3. Obagi Cosmeceuticals LLC.
• 10.4. L'Oreal Groupe
• 10.5. SkinCeuticals.
• 10.6. ZO Skin Health, Inc.
• 10.7. JMSR, Inc.
• 10.8. La Roche-Posay
• 10.9. Galderma
• 10.10. ELEVAI Labs, Inc.
• 10.11. Sebapharma
• 10.12. Cosmetic Skin Solutions.
• 10.13. AestheticsRX
• 10.14. RATIONALE.

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us